Cefuroxime Availability in 2026: A Provider Briefing

Cefuroxime (formerly Ceftin) remains a workhorse second-generation cephalosporin in outpatient and inpatient settings. It provides reliable broad-spectrum coverage for common community-acquired infections and is a guideline-recommended option for conditions ranging from acute bacterial sinusitis to early Lyme disease. However, the dynamics of the generic antibiotic market have introduced intermittent availability challenges that can affect your prescribing workflow.

This briefing summarizes the current Cefuroxime supply landscape, prescribing considerations, and practical tools for helping your patients access this medication in 2026.

Current Supply Status

As of early 2026, Cefuroxime is not on the FDA's drug shortage list. National supply of oral Cefuroxime Axetil (250 mg and 500 mg tablets) and oral suspension (125 mg/5 mL and 250 mg/5 mL) is generally adequate. Multiple generic manufacturers continue to produce oral formulations.

However, providers should be aware of the following dynamics:

• Injectable Cefuroxime Sodium (750 mg and 1.5 g vials) has historically been more vulnerable to supply disruptions than oral formulations. Hospital pharmacists may experience intermittent stock-outs of specific strengths.
• Localized retail shortages are reported periodically, particularly during peak respiratory illness season (October–March) when prescribing volume increases.
• The brand product Ceftin has been discontinued. All oral Cefuroxime is now generic.

Timeline of Recent Supply Events

Cefuroxime has not experienced a significant nationwide shortage comparable to drugs like amoxicillin (which had a widely reported shortage in 2022–2023). The injectable formulation has had intermittent supply issues tracked by ASHP, often linked to single-manufacturer production delays. Oral supply has remained relatively stable, though individual pharmacies may experience temporary stock-outs.

The broader trend affecting Cefuroxime is the contraction of the generic antibiotic manufacturing base. With thin margins and limited pricing power, some manufacturers have exited the market for low-cost generic antibiotics, reducing supply chain redundancy.

Prescribing Implications

When to Prescribe Cefuroxime

Cefuroxime remains an appropriate first-line or second-line choice for:

• Acute bacterial sinusitis: IDSA guidelines include Cefuroxime as a second-line option when amoxicillin-clavulanate is not suitable.
• Acute otitis media: Effective against H. influenzae, S. pneumoniae, and M. catarrhalis (including beta-lactamase producers).
• Community-acquired pneumonia: ATS/IDSA guidelines support Cefuroxime as an option for outpatient treatment.
• Early Lyme disease: Cefuroxime 500 mg BID for 14–21 days is a first-line alternative to doxycycline, particularly for patients who cannot take tetracyclines (pregnant women, children under 8).
• Uncomplicated UTIs: Effective against E. coli and Klebsiella spp., though typically not the first-line UTI antibiotic.
• Skin and soft tissue infections: Effective against S. aureus and S. pyogenes.

When to Consider Alternatives

If your patient reports that a pharmacy cannot fill Cefuroxime, consider the following evidence-based alternatives:

• Amoxicillin-Clavulanate (Augmentin): First-line for sinusitis and otitis media. Widely available, very affordable ($10–$20 generic). Broader beta-lactamase coverage.
• Cefdinir: Third-generation oral cephalosporin. Convenient once-daily dosing. Good option for respiratory infections and otitis media. Note: not effective for Lyme disease.
• Cefpodoxime: Third-generation oral cephalosporin with broader gram-negative coverage. Suitable for UTIs, respiratory infections, and gonorrhea.
• Doxycycline: First-line for early Lyme disease (except in pregnancy and children under 8). Also effective for many respiratory infections and skin infections.

For a patient-facing resource you can share: Alternatives to Cefuroxime.

Availability Picture: Oral vs. Injectable

Oral Cefuroxime Axetil

Generally available at most retail pharmacies. Multiple generic manufacturers maintain production. Pricing is competitive:

• Retail cash price: $17–$50 for 14 tablets (500 mg)
• With discount coupons: $11–$13 for 14 tablets (500 mg)
• With insurance: Tier 1 generic, typically $0–$15 copay

Injectable Cefuroxime Sodium

More susceptible to supply fluctuations. Hospital pharmacies should monitor ASHP drug shortage bulletins and maintain formulary flexibility. When injectable Cefuroxime is unavailable, consider cefazolin or ceftriaxone based on the clinical indication and local antibiogram data.

Cost and Access Considerations

Cefuroxime is one of the more affordable antibiotics on the market. Key points for patient counseling:

• Generic Cefuroxime has no manufacturer savings programs or copay cards (since there is no branded product).
• Patients without insurance can use free discount coupons from GoodRx, SingleCare, or RxSaver to reduce costs to $11–$13 per prescription.
• For financially hardship patients, resources like NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain databases of assistance programs and discount cards.
• No prior authorization or step therapy is required for Cefuroxime on most commercial and Medicare Part D plans.

Tools and Resources for Your Practice

Several tools can streamline the process of getting patients their Cefuroxime prescriptions:

Medfinder for Providers

Medfinder offers a provider-focused tool that checks real-time pharmacy stock. Before sending an e-prescription, you or your staff can verify that the patient's preferred pharmacy has Cefuroxime available — reducing callbacks and delays.

Patient Education Resources

Share these Medfinder articles with patients who have questions about their Cefuroxime prescription:

• What is Cefuroxime? Uses, dosage, and what you need to know
• Cefuroxime side effects: What to expect and when to call your doctor
• Cefuroxime drug interactions: What to avoid

Prescription Transfer Guidance

Remind patients that they can transfer their Cefuroxime prescription to any in-stock pharmacy without needing a new prescription. This is especially helpful when a patient's usual pharmacy is temporarily out of stock.

Looking Ahead

The generic antibiotic supply chain continues to face structural challenges — consolidation among manufacturers, thin margins, and global raw material dependencies. While Cefuroxime is not currently in shortage, proactive formulary planning and awareness of alternatives remain good practice.

The FDA's Drug Shortage Staff and ASHP Drug Shortage Resource Center provide updated information on supply disruptions. We recommend periodic review of these resources as part of antimicrobial stewardship workflows.

Final Thoughts

Cefuroxime remains a valuable antibiotic with a well-established safety profile and broad coverage. Supply is generally stable in 2026, but localized availability issues are possible. By maintaining awareness of alternatives, leveraging real-time stock-checking tools like Medfinder, and counseling patients on prescription transfer options, you can minimize treatment delays and ensure your patients get the antibiotics they need.

For a patient-facing overview of Cefuroxime availability: Cefuroxime shortage update: What patients need to know in 2026.